Geoff Meacham - Barclays Capital


Last quote by Geoff Meacham

We are downgrading MRK shares to Equal Weight from Overweight based on diminished upside potential from Keytruda, which is by far Merck's biggest value
share this quote
Oct 30 2017
Geoff Meacham has most recently been quoted in an article called Merck shares dive after multiple firms downgrade on cancer drug withdrawal. Geoff Meacham said, “Our prior thesis had assumed that Keytruda could drive better than expected growth over the intermediate term. We see less upside potential for Keytruda sales in lung cancer, the biggest immuno-oncology market. We don't think this means that immuno-oncology rivals will leapfrog Merck, but both Bristol and Roche could have front-line non-small cell lung cancer data in late 2017/early 2018 that could further weigh on sentiment.”. Geoff Meacham has been quoted a grand total of 3 times in 3 articles.
Automatically powered by Storyzy
Take our quote verification challenge and find out !

Quotes by Geoff Meacham

Quote Verifier
Check if the quote you read on social networks is authentic
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided

Quote :

Mistake :

Comments :